The United Kingdom (UK) recently announced a series of pilot programs that will test new approaches to medicines pricing, access, and adoption beginning as early as September 2026. One pilot will examine how certain innovative treatments that have already met safety, quality, and clinical standards – including therapies for rare conditions – can reach eligible National Health System (NHS) patients more quickly. Others will test whether the system should account for productivity gains from medicines, permit industry co-investment in screening and testing, and provide dedicated regional funding to improve uptake of priority therapies. The broader commitment is to double innovative medicines spending from 0.3 percent to 0.6 percent of gross domestic product (GDP) over the next decade. Yet the cumulative impact of these programs should only remind policymakers that central budgeting, particularly in health care, sacrifices patient access in pursuit of the correct bottom line.

The relevant backdrop is the UK-U.S. pharmaceutical pricing arrangement. Under that agreement, the UK committed to doubling its spending on new medicines as a share of GDP by 2036, increasing the share of the NHS budget spent on medicines from 10 percent in 2026 to 12 percent by 2036 and raising the net price paid for prospective new medicines by 25 percent. It also calls for lifting the National Institute for Health and Care Excellence’s (NICE) quality-adjusted life year (QALY) threshold from £20,000–£30,000 to £25,000–£35,000.

There is clear patient upside here. The announcement has already contributed to nine additional medicines being approved for NHS patients in England and Wales. NICE expects up to five extra medicines could be approved each year compared with the prior arrangements. Those figures are small, but they are not trivial. For patients with blood disorders, autoimmune diseases, cancers, or rare conditions, the difference between access and non-access is not a spreadsheet exercise. It is time, function, pain, survival, and the possibility of treatment when no good options remain.

But the pilots should not be mistaken as proof that foreign governments have finally accepted their duty to “pay their fair share” for pharmaceuticals, nor that they are focused on the patient alone. Rather, they should be better understood as a modest effort to loosen the consequences of a system that has long treated access to innovative medicines as a budget-management problem first and a patient-care problem second. It reveals the damage that follows when a national health system decides in advance how much medicine it is willing to tolerate, then fits patient access within that political constraint.

To be clear, the UK is not a repentant underpayer being rescued by Washington’s trade-policy savants. It is a single-payer system adjusting a series of government-set thresholds, access rules, and budgetary valves after years of political pressure. The quandary is not whether the UK was insufficiently generous to U.S. drugmakers. The quandary is whether any central government should be empowered to decide, in such a coordinated and mechanical fashion, how much access patients are allowed to have.

This is where the “free riding” argument goes wrong. Central governments are neither passive beneficiaries of U.S. pharmaceutical innovation nor inadvertent misers who simply need nudged to become better benefactor of global drug development. They are making deliberate allocation decisions. They decide what additional months of life, improved quality of life, or faster disease control are worth under a public budget. Once that value is assigned, medicines, physicians, and patients are forced to conform to it. The numbers look technical. The consequences are human.

The UK arrangement should also not serve to validate the same strategy by the United States against Germany. In June, the U.S. Trade Representative (USTR) initiated a Section 301 investigation into Germany’s alleged “persistent underpayment” for innovative pharmaceuticals, arguing that Germany’s policies may burden or restrict U.S. commerce. USTR specifically connected the Germany investigation to the UK arrangement and urged Germany to follow a similar path.

A bad foreign reimbursement model should not become the foundation for a bad U.S. trade policy. Germany’s system may well restrict patient access, distort incentives, and undervalue medicines. That is a critique of centralized health care financing, not a justification for tariff threats. If Germany chooses to ration access through reimbursement policy, the answer is not for the United States to convert that rationing dispute into an import-tax campaign.

Why? Because that course of action is not a coherent access policy. It is trade pressure masquerading as health care reform. Tariffs can raise costs, distort supply chains, privilege politically negotiated deals, and turn pharmaceutical coverage into a diplomatic bargaining exercise. Tariffs cannot cure rationing abroad, and they do not improve affordability at home by threatening to make imported medicines more expensive.

The UK pilots may help some patients receive medicines faster, but their existence is an indictment of the system that made such pilots necessary. A spending cap may look like fiscal discipline. A QALY threshold may look like objective analysis. A rebate formula may look like ordinary budget mechanics. But when these tools determine whether a patient can obtain a therapy, they are not just numbers on paper. They are government judgments about the value of human life, operationalized through coverage rules.

Britain’s pilot program is a reminder that centralized health systems can always adjust the rationing dial. It is not a reason for the United States to install one of its own, or to use tariffs to pressure other countries to turn theirs a little higher.

Chart Review: Is Health System Consolidation Imposing Higher Costs on Private Insurers?

Evan McLaughlin, Health Policy Intern

Recent KFF data show prices for hospital services rising faster for private insurers than for Medicare, with a divergence that became especially pronounced around 2022. From April 2019 to April 2026, the price of hospital services rose 30 percent for private insurers compared with 21 percent for Medicare. This divergence reflects both long-run structural differences and a sharper post-2022 acceleration in negotiated commercial rates. 

Structurally, the price gap reflects a reality of the U.S. health care system, in which Medicare prices are set by statute, while private insurance prices are determined by market negotiations between insurers and providers. Unlike Medicare, private insurers operate in a market where provider bargaining power can significantly influence prices. Substantial evidence points to health system consolidation as a leading factor driving increases in those prices. In just the past 14 years, the share of hospitals affiliated with a health system has risen from 56–69 percent, while the share of independent hospitals has fallen from 44–31 percent. As consolidation continues, private insurers may face reduced negotiating leverage, contributing to further increases in commercial health care costs.  

While consolidation created the underlying conditions for higher commercial rates, the initial post-pandemic period amplified this structural divide. According to KFF, elevated labor and supply expenses during the pandemic strengthened the case for higher negotiated commercial rates. Medicare price growth was also limited as a result of underestimating inflation when prospectively setting rates, reinforcing the structural divide at play.